aot2022v55i2

Acta Oncologica Turcica 2022; 55: 103-108
105
Table 1. Clinical and laboratory characteristics of
the 196 patients enrolled in the study at diagnosis
Patients Characteristics
Median age, y (range) 63 (35-85)
Gender, n (%)
• Male
• Female
Type of M component, n (%)
115 (58.7)
81 (41.3)
• IgG 101 (51.6)
• IgA 49 (25)
• IgM 2 (1)
• IgD 1 (0.5)
• Biclonal 1 (0.5)
• Light chain only 41(20.9)
• Non-secretory 1 (0.5)
R-ISS, n (%)
• I 34 (17.3)
• II 124 (63.3)
• III 38 (19.4)
Hemoglobin, g/dL (range) 9.7 (5.4-15.3)
β2-microglobulin, mcg/mL
(range)
5.6 (1.4-120)
Creatinine, mg/dL (range) 1 (0.4-11.2)
Calcium, mg/dL (range) 9.4 (5.5-15.4)
Albumin, g/dL (range) 3.6 (1.3-5.1)
Lactate dehydrogenase, U/L
(range)
194 (88-851)
Lytic lesion, n (%) 123 (62.8)
Plasmacytoma, n (%) 34 (17.3)
CD19(+), n (%) 57 (29.1)
CD20(+), n (%) 20 (10.2)
CD117(+), n (%) 57 (29.1)
CD56(+), n (%) 146 (74.5)
CD23(+), n (%) 23 (10.2)
CD45(+), n (%) 32 (16.3)
BCL-2(+), n (%) 60 (30.6)
BCL-2, B-cell lymphoma 2; CD, Cluster of Differentiation; Ig,
Immunoglobulin; R-ISS,The Revised International Staging
System.
Statistical Analysis
All statistical analyses were performed using
SPSS (IBM Corp. Released 2016. IBM SPSS
Statistics for Windows, Version 24.0.
Armonk, NY: IBM Corp.). Kolmogorov-
Smirnov tests were used to test the normality
of the data distribution. The data are expressed
as median, minimum, maximum, the
percentages and numbers. The Pearson chisquare
test was used to compare the
categorical variables. Mann-Whitney U test
was used for comparison of continuous
variables between the CD23 positive and
CD23 negative groups. A two-sided p value
<0.05 was considered to be statistically
significant.
Results
Clinical and laboratory characteristics of the
196 patients at diagnosis are shown in Table
1. The patients consisted of 115 men and 81
women ages ranging from 35 to 85 years.
According to the R-ISS, 17.3% of patients
were stage I; 63.3%, stage II; and 19.4%, stage
III. Of 196 PCMs, 23 (10.2%) were found to
be CD23 positive by MFC at diagnosis. As
shown in Table 2, age, sex, creatinine,
albumin, lactate dehydrogenase, beta-2
microglobuline and calcium level, bone
lesions, expression of surface antigens were
similar for patients with CD23 positive and
for those with CD23 negative. Compared with
those of CD23 negative patients, in CD23
positive patients, the rate of patients with
hemoglobin value <10 g/dl was less (30% vs
55.7%, P=0.029) and CD56 positive patient
rate was greater (35% vs. 7.4%, P<0.001).
There was no significant relationship between
t (11;14) and the CD23 level (p>0.05). There
were no statistically significant differences
between R-ISS score and the CD45, CD56,
CD117, CD19, CD20, BCL-2 levels (all
p>0.05); whereas CD23 levels were more
expressed in R-ISS 1 score patients compared
to the R-ISS 2 and R-ISS 3 patients (p=0.017).
www.actaoncologicaturcica.com
Copyright©Ankara Onkoloji Hastanesi